Renalytix

Renalytix is an in vitro diagnostics company, focused on development and translation to clinical practice of precision diagnostics tests for Chronic Kidney Disease in order to optimize clinical management leading to improved patient outcomes and lower healthcare costs. We have developed the KidneyIntelX platform which combines data from blood or urine-based biomarkers with patient data from electronic health records to generate personalized assessment of risk of disease progression. With operations located in Europe and US, Renalytix will play a leading role in translating the scientific and clinical research findings to diagnostics products for clinical use.

People involved in Prime-CKD

Fergus Fleming

Fergus Fleming, Chief Technology Officer Fergus Fleming has served as Renalytix’s Chief Technical Officer since its inception. Fergus has over 30 years’ experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific, Trinity Biotech plc, and EKF Diagnostics. Fergus has extensive experience in the design and manufacture in vitro diagnostics instruments and reagents.

Dr. Sharon Stapleton PhD

Dr. Sharon Stapleton PhD, Director of Scientific and Clinical Research and Development. Sharon has over 15 years’ experience working with both early-stage start-ups and global diagnostics companies, including leadership positions with EKF Diagnostics, OncoMark (acquired by Cepheid Inc.) and Trinity Biotech. She is an expert in the design and development of immunoassays and has extensive experience managing multi-site projects including clinical studies, new product introduction and regulatory submissions. Dr Stapleton has a PhD in Applied Biochemistry from Dublin City University, Ireland.

Dr Katherine Edwards

Dr Katherine Edwards, Research and Development Scientist, Junior Researcher. Currently responsible for design, execution and reporting of development and validation studies for novel biomarkers in CKD. Previously, Katherine was a product engineering scientist for Trinity Biotech plc. and was involved with new product transfer, validation of new products, clinical studies and regulatory submissions to the FDA and WHO, as well as, for CE marking. Katherine’s PhD focused on exploring new regulators of innate immune signalling pathways with a particular focus on inflammasomes.

Dr. Steven G. Coca, Nephrologist

Dr. Steven G. Coca, Nephrologist, is a Professor of Medicine and the Associate Chair for Clinical and Translational Research for the Department of Medicine at the Icahn School of Medicine at Mount Sinai. His research has focused on using novel biomarkers to improve risk stratification in patients with acute kidney injury and chronic kidney disease. Dr. Coca has been an active investigator in several large NIH-funded consortia (TRIBE-AKI, ASSESS-AKI, CKD Biocon, KPMP). He is a co-founder of Renalytix.

Dr. Girish N. Nadkarni, Nephrologist

Dr. Girish N. Nadkarni, Nephrologist, is the Fishberg Professor in Medicine at the Icahn School of Medicine at Mount Sinai, Chief of the Division of Data Driven and Digital Medicine (D3M) and Director of the Charles Bronfman Institute of Personalized Medicine. Dr. Nadkarni has authored 300 peer-reviewed scientific publications. He is the principal investigator for several NIH funded R01/U01 grants. Dr. Nadkarni is also the scientific co-founder of several investor-backed companies.